This inventor holds 4 USPTO granted patents. Top assignee: Mitsui Toatsu Chemicals, Incorporated. Active years: 1991-1993.
Location History:
- Mobara, JP (1991 - 1993)
- Takashi, JP (1993)
Company Filing History:
Years Active: 1991-1993
Title: Fumiaki Ikeda: Innovator in Neuropharmacology
Introduction
Fumiaki Ikeda is a notable inventor based in Mobara, Japan, recognized for his contributions to neuropharmacology through his innovative work in catechol derivatives. With a total of four patents, Ikeda's research focuses on developing pharmaceutical preparations that aim to combat regressive disorders of the central nervous system, including Alzheimer’s disease.
Latest Patents
Ikeda's recent patents elaborate on catechol derivatives that are essential for stimulating nerve growth factor production in specific brain tissues. One significant patent details these derivatives' preventive and therapeutic effects against central nervous system disorders, specifically relating to senile dementia of the Alzheimer type. His innovative formulations not only provide therapeutic benefits but also include comprehensive methods for synthesis and data on their physiological activity and toxicity. These developments mark a significant stride in addressing age-related cognitive decline, enhancing prospects for treatment and management of Alzheimer's disease.
Career Highlights
As an inventor at Mitsui Toatsu Chemicals, Incorporated, Ikeda has dedicated his career to research that bridges chemistry and medicine. His innovative approach has led to pivotal advancements in understanding how chemical compounds can influence neurological health, representing a blend of scientific inquiry and practical application within the pharmaceutical industry.
Collaborations
Throughout his career, Fumiaki Ikeda has collaborated with esteemed colleagues such as Shigenobu Nakayama and Nobuyuki Fukazawa. Together, they have contributed to the development of novel pharmaceutical solutions, fostering an environment of innovation that addresses critical health challenges in neuropharmacology.
Conclusion
Fumiaki Ikeda stands as a prominent figure in the realm of neuropharmaceutical innovations. His work with catechol derivatives has opened new avenues for preventing and treating Alzheimer's disease, showcasing the intersection of chemical research and neurological health. As research continues to evolve, Ikeda’s contributions will undoubtedly lead to greater understanding and advancements in the field.